While IV infusion of anti-PD-1/PD-L1 mAb induces swift onset of therapeutic effects [92] and enables them to bypass absorption and degradation constraints encountered by other means of administration [93], it also allows for off-tumor accumulation in healthy tissues that increases the risk of irAEs [94]. The gene discussed is CD274; the disease is neoplasm.